Acute Effects of Cholecystokinin Tetrapeptide on Brain Stem Auditory Evoked Potentials in Healthy Volunteers

This study investigated the effects of continuous slow intravenous infusion of cholecystokinin tetrapeptide (CCK-4) on brain stem auditory evoked potentials (BSAEP) in healthy subjects. Twenty-four subjects, 15 females and 9males, were assigned to infusion with either placebo or CCK-4 in a randomized, double-blind, parallel group design. BSAEPs, mood, physical symptoms, and vital signs were assessed once before infusion and at 10 min and 40 min after the onset of infusion. In the 16 subjects (N = 8, CCK-4; N = 8, placebo) CCK-4, compared to placebo, delayed peak I latency during early infusion, slowed the latencies of peaks III and V, and decreased the amplitude of peak III throughout the infusion. No significant treatment differences were observed with respect to symptoms, mood, or cardiovascular measures. These preliminary findings suggest that CCK-4 may interfere with information processing in the brain stem auditory pathways and that prolonged intravenous CCK-4 administration may be a useful challenge paradigm for investigating CCK’s modulatory role on brain stem mechanisms mediating anxiety and panic in humans.

Key words

Cholecystokinin - CCK-4 - brain stem auditory evoked potentials - anxiety, panic

References

• 1 Abelson J L, Nesse R M. Pentagastrin infusions in patients with panic disorder. I: Symptoms and cardiovascular responses.  Biol Psychiatry. 1994;  36 73-83
• 2 Albus M. Cholecystokinin.  Prog Neuro-Psychopharmacol and Biol Psychiatry. 1988;  12 S5-21
• 3 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition ed Washington, D.C; American Psychiatric Association 1994
• 4 Bobillier P, Seguin S, Petitjean F, Salvert D, Touret M, Jouvet M. The raphe nuclei of the cat brainstem: a topographical atlast of their efferent projections as revealed by autoradiography.  Brain Res. 1976;  113 449-486
• 5 Bourin M, Malinge M, Guitton B. Provocative agents in panic disorder.  Therapie. 1995;  50 301-306
• 6 Bradweyn J, Kosycki D, Meterissian G. Cholccystokinin-tetrapeptide induces panic attacks in patients with panic disorder.  Can J Psychiatry. 1990;  35 83-85
• 7 Bradwejn J, Koszycki D, Bourin M. Dose ranging study of the effects of cholecystokinin in healthy volunteers.  J Psychiatry Neurosci. 1991;  16 91-95
• 8 Bradwejn J, Koszycki D, Payeur R. Cholecystokinin-tetrapeptide: A provocation agent for research in panic disorders?. In Briley M, Files S (eds) New Concepts in anxiety. MacMillan Press London; 1991
• 9 Bradwejn J, Koszycki D, Shriqui C. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder.  Arch Gen Psychiatry. 1991;  7 603-610
• 10 Bradwejn J, Koszycki D. The cholecystokinin hypothesis of anxiety and panic disorder. In Reeve JR Jr, Solomon TE, Go VL (eds) Cholecystokinin. The New York Academy of Sciences New York, NY; 1994
• 11 Branchereau R, Champagnat J, Roques B, Denavit-Saubie M. CCK modulates inhibitory synaptic transmission in the solitary complex through CCK B sites.  Neuroeport. 1992;  3 909-912
• 12 Caspary D, Havey D, Faingold C. Effects of microiontophoretically applied glycine and GABA on neuronal response pattern in the cochlear nuclei.  Brain Res. 1979;  172 179-185
• 13 Charney D S, Heninger G R, Jatlow P. Increased anxiogenic effects of caffeine in panic disorders.  Arch Gen Psychiatry. 1985;  42 233-243
• 14 Charney D S, Woods S W, Goodman W K, Heninger G R. Neurobiological mechanisms of panic anxiety: biochemical and behavioral correlates of yohimbine-induced panic attacks.  Am J Psychiatry. 1987;  144 1030-1036
• 15 Charney D S, Woods S W, Krystal J H, Nagy L M, Heninger G R. Noradrenergic neuronal dysregulation in panic disorder: the effects of intravenous yohimbine and clonidine in panic disorder patients.  Acta Psychiat Scand. 1992;  86 273-282
• 16 Chiappa K. Evoked potentials in clinical medicine, Lippincott - Raven Publishers (3rd Ed). Philadelphia; 1997
• 17 Coplan J D, Lydiard R B. Brain circuits in panic disorder.  Biol Psychiatry. 1998;  44 1264-1276
• 18 Crawley J N, Corwin R L. Biological actions of cholecystokinin.  Peptides. 1994;  15 731-755
• 19 Crawley J N. Interactions between cholecystokinin and other neurotransmitter systems. In Bradwejn J, Vasar E (eds) Cholecystokinin and anxiety: from neuron to behavior. Springer Verlag Austin; 1995
• 20 de Montigny C. Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers.  Arch Gen Psychiatry. 1989;  46 511-517
• 21 Derogatis L, Lipman R, Richels K. The Hopkins Symptom Checklist (HSCL): a measure of primary symptom dimensions. In Pichot P (ed) Psychological measurement: modern problems in pharmacopsychiatry. Karger Basel, Switzerland; 1979
• 22 Don M, Eggermont J. Analysis of the click-evoked brainstem potentials in man using high-pass noise masking.  J Accost Soc Am. 1978;  63 1084-1092
• 23 Epstein C M. The use of brain stem auditory evoked potentials in the evaluation of the central nervous system.  Neurol Clin. 1998;  6 771-790
• 24 Eybalin M, Parnaud C, Geffard M, Pujoi R. Immunoclectron miscroscopy identiifes several types of GABA- contaning efferent synapses in the guinea-pig organ of Corti.  Neurosci. 1988;  24 29-38
• 25 Fex J, Altschuler R, Kachar B, Wenthold R, Zempel J. GABA visualized by immunocytochemistry in the guinea pig cochlea in axons and endings of efferent neurons.  Brain Res. 1986;  366 106-117
• 26 Fitzgerald J D. Pentagastrin as a stimulant of maximal gastric acid response in man.  Lancet. 1967;  1(7485) 291-295
• 27 Gorman J M, Liebowitz M R, Fyer A J, Stein J. A neuroanatomical hypothesis for panic disorder.  Am J of Psychiatry. 1989;  146 148-161
• 28 Harro J, Vasar E, Bradwejn J. CCK in animal and human research on anxiety.  Trends Pharmacol Sci. 1993;  14 244-249
• 29 Harro J, Vasar E, Koszycki D, Bradwejn J. Cholecystokinin in panic and anxiety disorders.  Adv Biol Psychiatry. 1995;  1 235-262
• 30 Hendry S, Jones E, DeFelipe J, Schmochel D, Brandon C, Emson P. Neuropeptide-containing neurons of the cerebral cortex are also GABAergic.  Proc Natl Acad Sci. 1984;  81 6526-6530
• 31 Javanmard M, Shlik J, Kennedy S H, Vaccarino F J, Houle S, Bradwejn J. Neuroanatomic correlates of CCK- 4-induced panic attacks in healthy humans: a comparison of two time points.  Biol Psychiatry. 1999;  45 872-822
• 32 Knott V J, Lapierre Y D. Effects of lactate-induced panic attacks on brain stem auditory evoked potentials.  Neuropsychobiology. 1986;  16 9-14
• 33 Knott V J, Bakish D, Barkley J. Brainstem evoked potentials in panic disorder.  J Psychiatry and Neurosci. 1994;  19 301-306
• 34 Levy D, Kimhi R, Barak Y, Demmer M, Harel M, Elizur A. Brainstem auditory evoked potentials of panic disorder pateints.  Neuropsychobiology. 1996;  33 164-167
• 35 Liebowitz M R, Gorman J M, Fyer A, Dillon D, Levitt M, Klein D F. Possible mechanisms for lactate’s induction of panic.  Am J Psychiatry. 1986;  143 495-502
• 36 McDonald A, Pearson J. Coexistence of GABA and peptide immunoractivity in non-pyramidal neurons of the basolateral amygdala.  Neuroscience Lett. 1989;  100 53-58
• 37 Noble F, Roques B P. CCK-B receptor: chemistry, molecular biology, biochemistry and pharmacology.  Prog Neurobiology. 1999;  58 349-379
• 38 Papp L A, Klein D F, Martinez J, Schneier F, Cole R, Liebowitz M, Hollander E, Tyer A, Jordan E, Gorman J. Diagnostic and substance specificity or carbon dioxide-induced panic.  Am J Psychiatry. 1993;  150 250-257
• 39 Parnaud C, Eybalin M, Geffard M, Pujoi R. Light and electron microscopic localization of GABA- immunostraining in efferent fibres of the organ of Corti.  Neurosci Lett Suppl. 1986;  26 S284
• 40 Picton T, Hilliard S, Krausz H, Galambos R. Human auditory evoked potentials. I: Evaluation of components.  Electroencephalogy Clin Neurophysio. 1974;  36 179-190
• 41 Pohl R, Yeragani V K, Balon R, Rainey J, Lycaki H, Ortiz A, Berchou R, Weinberg P. Isoproterenol-induced panic attacks.  Biol Psychiatry. 1988;  24 891-902
• 42 Pyke R E, Greenberg H S. Norepinephrine challenges in panic patients.  J Clin Psychopharmacol. 1986;  6 279-285
• 43 Rehfeld J F, Nielson F C. Molecular forms and regional distribution of cholecystokinin in the central nervous system. In Bradwejn J, Vasar E (eds) Cholecystokinin and anxiety: from neuron to behavior. Springer Verlag Austin; 1995
• 44 Shlik J, Vasar E, Bradwejn J. Cholecystokinin and psychiatric disorders. Role in aetiology and potential of receptor antagonists in therapy.  CNS Drugs. 1997;  8 134-152
• 45 Shlik J, Koszycki D, Bradwejn J. Decrease in short-term memory ufnction induced by CCK-4 in healthy volunteers.  Peptides. 1998;  19 969-975
• 46 Shlik J, Zhou Y, Koszycki D, Vaccarino F J, Bradwejn J. Effects of CCK-4 infusion on the acoustic eye-blink startle and psychophysiological measures in healthy volunteers.  J Psychopharmacol. 1999;  13 385-390
• 47 Somogyi L, Hodgson A, Smith A, Nunzi M, Gorio A, Wu J. Different populations of GABA-ergic neurons in the visual cortex and hippocampus of CAT contain somatostalin or cholecystokinin-immunoreactive material.  J Neursci. 1984;  4 2590-2603
• 48 Thompson G, Cortez A, Lam D. Localization of GABA immunoreactivity in the auditory brainstem of guinea pigs.  Brain Res. 1985;  339 119-122
• 49 van Megan H JGM, Westenberg H GM, den Boer J A, Haigh J RM, Traub M. Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients.  Psychopharmacology. 1994;  114 449-455
• 50 van Megan H JGM, Westenberg H GM, Den Boer J A, Kahn R S. The panic-inducing properties of the cholecystokinin tetrapeptide CCK-4 in patients with panic disorder.  Eur Neuropsychopharmacol. 1996;  6 187-194
• 51 Vetter D, Adams J, Mirgiaini E. A dual efferent GABAergic projection to the rat cochlea.  Soc Neurosci Ab. 1986;  12 979
• 52 Westerberg B, Roberson J, Stach B. A double-blind placebo-controlled trial of baclofen in the treatment of tinnitus.  Am J Otol. 1996;  17 896-903
• 53 Yeudall L, Schopflocher D, Sussman P, Barabash W, Warneke L, Gill D, Oho W, Howarth B, Tormanson P. Panic attack syndrome with and without agoraphobia: neuropsychological and evoked potential correlates. In Flor- Henry P, Gruzedier J (eds) Laterality and psychopathology Elsevier New York; 1983
• 54 Gormon J, Kent J, Sullivan G, Coplan J. Neuroanatomical hypothesis of panic disorder, revised.  Am J Psychiatry. 2000;  157 493-505
• 55 Tsutsumi T, Akiyoshi J, Hikichi T, Kiyota A, Kohno Y, Katsurasi S, Yamamoto Y, Isogawa K, Nagayama H. Suppression of conditional fear by administration of CCKB receptor antisense oligodeoxynucleotide into the lateral ventricle.  Pharmacopsychiatry. 2001;  6 232-237